Vertex Pharmaceuticals (VRTX) Gross Profit (2010 - 2026)

Vertex Pharmaceuticals' Gross Profit history runs 17 years deep, the most recent figure standing at $2.6 billion for Q1 2026.

• In Q1 2026, Gross Profit rose 7.76% year-over-year to $2.6 billion; the TTM figure through Mar 2026 stood at $10.5 billion (up 10.35% YoY), while the FY2025 annual figure was $10.4 billion, up 9.07% from the prior year.
• Gross Profit was $2.6 billion for Q1 2026 at Vertex Pharmaceuticals, down from $2.7 billion in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $2.7 billion in Q4 2025 to a low of $1.9 billion in Q1 2022.
• Historically, Gross Profit has averaged $2.3 billion across 5 years, with a median of $2.3 billion in 2024.
• The sharpest annual moves came in 2022 and 2025: Gross Profit gained 23.57% in 2022, then increased 2.52% in 2025.
• A 5-year view of Gross Profit shows it stood at $2.0 billion in 2022, then gained by 6.45% to $2.1 billion in 2023, then grew by 15.76% to $2.5 billion in 2024, then climbed by 9.46% to $2.7 billion in 2025, then declined by 4.77% to $2.6 billion in 2026.
• The last three Gross Profit figures came in at $2.6 billion (Q1 2026), $2.7 billion (Q4 2025), and $2.7 billion (Q3 2025), per Business Quant data.